Blueprint Medicines’ Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis
December 10, 2024
Blueprint Medicines Corporation announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT in advanced systemic mastocytosis (advanced SM), and reflect the